Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF)

Żelazny, Przemysław, Filipczak, Joanna, Sygacz, Oliwer, Bróż, Sebastian, Dankiewicz, Sara, Swora, Aleksandra, Borowik, Joanna, Brodowski, Wojciech, Pawłowski, Piotr, Basta-Arciszewska, Katarzyna. Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF). Journal of Education, Health and Sport. 2022;12(9):583-588. eISSN 2391-8306. DOI http://dx.doi.org/10.12775/JEHS.2022.12.09.068

https://apcz.umk.pl/JEHS/article/view/39770

https://zenodo.org/record/7062892

 

 

 

 

 

The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of December 21, 2021. No. 32343.

Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical Culture Sciences (Field of Medical sciences and health sciences); Health Sciences (Field of Medical Sciences and Health Sciences).

Punkty Ministerialne z 2019 - aktualny rok 40 punktów. Załącznik do komunikatu Ministra Edukacji i Nauki z dnia 21 grudnia 2021 r. Lp. 32343. Posiada Unikatowy Identyfikator Czasopisma: 201159.

Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).

© The Authors 2022;

This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike.

(http://creativecommons.org/licenses/by-nc-sa/4.0/) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 21.08.2022. Revised: 02.09.2022. Accepted: 08.09.2022.

 

 

 

 

 

Angiotensin Receptor Antagonist-Neprilysin Inhibitor (ARNI) therapy as a new hope in the population of people with heart failure with reduced ejection fraction (HFrEF)

Terapia skojarzona Antagonistą Receptora Angiotensyny oraz Inhibitorem Neprylizyny (ARNI) jako nowa nadzieja w populacji pacjentów z niewydolnością serca z obniżoną frakcja wyrzutową lewej komory (HFrEF)

 

Authors:
Przemysław Żelazny

1 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ w Lublinie

https://orcid.org/0000-0001-6794-9112 | przemo.zelazny@gmail.com 

 

Joanna Filipczak

Absolwent Uniwersytetu Medycznego w Lublinie

https://orcid.org/0000-0002-3512-8368 | joannafilipczak70@gmail.com 

 

Oliwer Sygacz

Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie

https://orcid.org/0000-0003-3245-945X | oliwer.sygacz@gmail.com

 

Sebastian Bróż
Wojewódzki Szpital Specjalistyczny Nr 1 imienia Fryderyka Chopina w Rzeszowie

https://orcid.org/0000-0002-6191-2535 | sebastianbroz223@gmail.com 

 

Sara Dankiewicz
Wojewódzki Szpital Specjalistyczny Nr 1 imienia Fryderyka Chopina w Rzeszowie
https://orcid.org/0000-0002-9208-8462 |  saradankiewicz96@gmail.com 

 

Aleksandra Swora

Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie

https://orcid.org/0000-0002-6171-0386 | ola.swora@gmail.com

 

Joanna Borowik

Samodzielny Publiczny Szpital Kliniczny nr 1 w Lublinie

https://orcid.org/0000-0001-8369-6207 | joannaa.borowik@gmail.com 

 

 

Wojciech Brodowski

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Lublinie

https://orcid.org/0000-0003-0756-387X | brodowski.wojciech@gmail.com 

 

Piotr Pawłowski

Student, Faculty of Medicine, Medical University of Lublin

https://orcid.org/0000-0002-1197-7218 | pawlowskipiotr56@gmail.com 

 

Katarzyna Basta-Arciszewska

Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego  Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie

https://orcid.org/0000-0002-7759-1588 | kasiabasta01@gmail.com

 

Abstract

Introduction: Heart failure affects an estimated 23 million people, as many as 50% of whom suffer from a heart failure with reduced ejection fraction (HFrEF), in which the left ventricle ejection fraction is <40% and is accompanied by clinical symptoms. Given the high mortality rate in this group of patients and the continuous suboptimal control of the condition, novel pharmacotherapy regimens are needed to slow the progression of the disease. Preliminary studies report a positive effect of including an angiotensin receptor antagonist and neprilysin inhibitors (ARNIs) in this group of patients.

Aim of the study: The aim of the study was to summarize the benefits of ARNI in a group of patients with HFrEF.

Methods and materials: This article is based on the literature found in PubMed Database with use of keywords such as “ARNI”, “neprilysin inhibition”, HFrEF”, “heart failure”

Results: The benefits of ARNI therapy in patients with HFrEF originate from reversing myocardial remodeling and increasing left ventricular ejection fraction. ARNI therapy is associated with reduced number of hospitalizations and a lower need for intensive treatment. In addition, ARNI use reduces the risk of cardiovascular death and is responsible for lower overall mortality rate compared to pharmacotherapy with angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor antagonists (ARBs).

Conclusion: ARNIs in patients with HFrEF have a positive effect on the rate of cardiovascular hospitalization, as well as reducing cardiovascular-related mortality and total mortality. Future research studies should evaluate the predictive factors of response to treatment with this group of drugs using larger groups of patients.

Keywords: „ARNI”; „neprilysin inhibition”; „HFrEF”; „heart failure”